“…The mapped literature highlighted the multidimensionality and versatility of digital therapeutics by showcasing their relative advantages compared with their competitors. At the patient level, the most reported relative advantages were improvements in health outcomes and shortened disease duration through novel health care options, faster diagnoses, decrease in adverse medical events, and improved monitoring of clinical and patient-reported outcome measures [ 11 , 17 , 41 , 43 , 45 , 47 - 49 , 53 , 60 , 61 , 69 , 71 , 74 , 80 , 81 , 88 , 92 , 94 , 95 , 100 , 102 , 105 , 124 , 128 , 130 , 132 , 133 , 135 , 137 , 138 , 146 , 153 , 163 , 172 , 173 , 179 , 189 , 202 , 207 , 218 , 224 , 226 , 228 , 229 , 231 , 232 , 234 , 239 - 242 , 244 , 246 , 248 , 257 , 260 , 262 , 263 , 265 , 266 , 270 , 275 ], a...…”